Single-Nucleus RNA Sequencing Reveals Stage-Specific Tumor Microenvironment Remodeling in TKI–Resistant EGFR-Mutant Lung Adenocarcinoma

Authors:
  • XZXinyue Zhang
    Xinyue Zhang
  • PLPei-Chih Lee
    Pei-Chih Lee
  • YYYang Yang
    Yang Yang
  • CGChenxu Guo
    Chenxu Guo
  • HCHung-Chih Chang
    Hung-Chih Chang
  • WCWei-Chung Cheng
    Wei-Chung Cheng
  • JZJian Zhang
    Jian Zhang
  • SJSiqi Ji
    Siqi Ji
  • XCXinran Chen
    Xinran Chen
  • HMHongxue Meng
    Hongxue Meng
  • MHMien-Chie Hung
    Mien-Chie Hung

Abstract
Although EGFR tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with EGFR-mutant lung adenocarcinoma, most individuals harbor residual disease (RD) after treatment that inevitably leads to tumor progression due to acquired resistance. To elucidate the cellular dynamics driving therapy resistance, we utilized FFPE-compatible single-nucleus RNA sequencing (snRNA-seq) paired with multiplexed immunohistochemistry (mIHC) for spatial analysis. This approach allows us to map the cellular niches across the treatment trajectory from treatment-naive to RD and progressive disease (PD) stages. Our analysis revealed that beyond the survival of known TOP2A+/AURKA+ proliferative subclones, EGFR inhibition drives a specific subset of tumor cells to adopt a plastic, alveolar type II-like progenitor state that is maintained across all treatment stages, suggesting a novel adaptive mechanism for drug resistance. Crucially, we identified RD not as a dormant phase, but as a period of active tissue remodeling that serves as the structural foundation for resistance. This phase is driven by CTHRC1+ cancer-associated fibroblasts (CAFs) that produce extensive extracellular matrix, forming a physical barrier that shields tumor cells from immune infiltration. Spatial analysis confirmed that these fibroblasts and myeloid cells construct a protective environment that excludes cytotoxic T cells during RD. By redefining RD as an active stage where fibroblast-generated barriers shield cancer cells from immune attack, our findings identify this stromal remodeling as a critical therapeutic window. Disrupting this fibroblast-mediated shielding during RD could restore T-cell infiltration and cytotoxic activity, potentially eradicating residual tumor cells and preventing the evolution of clinical resistance.